Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Hepatocellular Carcinoma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 82 results found since Jan 2013.

5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
In conclusion, our findings suggest that 3p-siRNA could act as a powerful bifunctional antiviral molecule with potential for developing a promising therapeutic against chronic HBV infection. PMID: 24099962 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - October 4, 2013 Category: Drugs & Pharmacology Authors: Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z Tags: Eur J Pharmacol Source Type: research

Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
In conclusion, TPGS-coated cationic liposomes with Bcl-2 siRNA corona had the capacity to inhibit MDR dual-pathways and subsequently improved the anti-tumor activity of the chemotherapeutic agent co-delivered to a level that cannot be achieved by inhibiting a MDR single way.Graphical abstract
Source: Asian Journal of Pharmaceutical Sciences - November 13, 2019 Category: Drugs & Pharmacology Source Type: research

Development of a simple, biocompatible and cost-effective Inulin- Diethylenetriamine based siRNA delivery system.
In conclusion, we developed a novel inulin-based siRNA delivery system able to efficiently release siRNA in JHH6 with negligible cytotoxicity thus opening the way for further testing in more complex in vivo models. PMID: 25845631 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - April 3, 2015 Category: Drugs & Pharmacology Authors: Sardo C, Farra R, Licciardi M, Dapas B, Scialabba C, Giammona G, Grassi M, Grassi G, Cavallaro G Tags: Eur J Pharm Sci Source Type: research

Pharmacokinetics and Biodistribution of Recently-Developed siRNA Nanomedicines.
Abstract Small interfering RNA (siRNA) is a promising drug candidate, expected to have broad therapeutic potentials toward various diseases including viral infections and cancer. With recent advances in bioconjugate chemistry and carrier technology, several siRNA-based drugs have advanced to clinical trials. However, most cases address local applications or diseases in the filtering organs, reflecting remaining challenges in systemic delivery of siRNA. The difficulty in siRNA delivery is in large part due to poor circulation stability and unfavorable pharmacokinetics and biodistribution profiles of siRNA. This rev...
Source: Advanced Drug Delivery Reviews - December 10, 2015 Category: Drugs & Pharmacology Authors: Park J, Park J, Pei Y, Xu J, Yeo Y Tags: Adv Drug Deliv Rev Source Type: research

Inhibitory Effect of Aptamer-Carbon Dot Nanomaterial-siRNA Complex on the Metastasis of Hepatocellular Carcinoma Cells by Interfering with FMRP
Eur J Pharm Biopharm. 2022 Mar 29:S0939-6411(22)00061-3. doi: 10.1016/j.ejpb.2022.03.013. Online ahead of print.ABSTRACTUsing small interfering RNA (siRNA) for the specific gene-silencing has been a novel therapeutic method for the treatment of incurable diseases such as malignancies. However, it remains a challenge whether siRNA can be safely and effectively delivered into target cells. Therefore, we synthesized fluorescent carbon dots (CDs) as a gene vector at the siRNA delivery system that induced efficient gene knockdown in vitro while binding aptamer AS1411 to resolve the difficulty in cell targeting. We found that CD...
Source: European Journal of Pharmaceutics and Biopharmaceutics - April 1, 2022 Category: Drugs & Pharmacology Authors: Xiaoliang Zhao Jie Yang Jing Zhang Xiangyun Wang Lulu Chen Chao Zhang Zhifa Shen Source Type: research

Glycyrrhetinic acid-modified graphene oxide mediated siRNA delivery for enhanced liver-cancer targeting therapy.
Abstract Graphene oxide (GO) has attracted huge attention in biomedical field in recent years. However, limited attempts have been invested in utilizing GO on active targeted delivery for gene therapy in liver cancer treatments. Glycyrrhetinic acid (GA) has been reported to be widely used as a targeting ligand to functionalize nanomaterials to treat hepatocellular carcinoma. In this article, GA is employed as a liver targeting ligand to construct GA, polyethylene glycol (PEG), polyamidoamine dendrimer (Dendrimer) and nano-graphene oxide (NGO) conjugate (GA-PEG-NGO-Dendrimer, GPND) for siRNA delivery for the first ...
Source: European Journal of Pharmaceutical Sciences - August 21, 2019 Category: Drugs & Pharmacology Authors: Qu Y, Sun F, He F, Yu C, Lv J, Zhang Q, Liang D, Yu C, Wang J, Zhang X, Xu A, Wu J Tags: Eur J Pharm Sci Source Type: research

Evaluation of therapeutic effect of targeting nanobubbles conjugated with NET-1 siRNA by shear wave elastography: an in vivo study of hepatocellular carcinoma bearing mice model.
In conclusion, TNBS conjugated with NET-1 siRNA inhibited tumor growth and prolonged the life of experimental animals. SWE provided a noninvasive and real time imaging method to detect the changes in tumor development. PMID: 31544556 [PubMed - in process]
Source: Drug Delivery - September 25, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Biocompatible co-loading vehicles for delivering both nanoplatin cores and siRNA to treat hepatocellular carcinoma
Publication date: Available online 26 October 2019Source: International Journal of PharmaceuticsAuthor(s): Minsi Li, Pengxuan Zhao, Ting Fan, Yan Chen, Xiaojuan Zhang, Chuanchuan He, Tan Yang, Robert J. Lee, Muhammad Waseem Khan, Shahid Masood Raza, Xiang Ma, Yao Lu, Guangya XiangAbstractBmi-1 is a gene related to malignant transformation in hepatocellular carcinoma (HCC). The liver cancer cells developed the ability to tolerate CDDP treatment with the elevation of Bmi-1. Bmi-1 is also an oncogene promoting malignance of tumor and an anti-cancer target in many studies. Herein, a biocompatible nanocarrier was designed in th...
Source: International Journal of Pharmaceutics - October 26, 2019 Category: Drugs & Pharmacology Source Type: research

The Codelivery of siRNA and QDs by pH-Responsive Micelle for Hepatoma Cancer Cells
In this study, a pH-responsive micelle based on polycaprolactone-block–poly 2-(dimethylamino)ethyl methacrylate (PCL-PDEM) cationic copolymer was developed to carry short interfering RNA (siRNA) for silencing interleukin 8 (IL-8) gene in hepatoma cancer cells. The transfection efficiency of the PCL-PDEM-siRNA/quantum dots (QDs) nanoplex has reached about 70%, and the expression level of IL-8 decreased about 63%. Furthermore, the codelivery of QDs and siRNA has been realized, which is beneficial to visualize the process of siRNA delivery. No considerable cytotoxicity from the nanoparticles has been observed, indicating th...
Source: Frontiers in Pharmacology - October 9, 2019 Category: Drugs & Pharmacology Source Type: research

Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
CONCLUSIONS: Our data demonstrated that VEGF silencing could suppress cells proliferation, promote cells apoptosis and reduce HCC angiogenesis through inactivation of VEGF/PI3K/AKT signaling pathway. PMID: 26744866 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 15, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): Qian-Yu Zhang, Pui Yan Ho, Mei-Juan Tu, Joseph L. Jilek, Qiu-Xia Chen, Su Zeng, Ai-Ming Yu Recently we have established a novel approach to produce bioengineered noncoding RNA agents (BERAs) in living cells that carry target RNAi molecules (e.g., siRNA and miRNA) and thus act as “prodrugs”. Using GFP-siRNA-loaded BERA (BERA/GFP-siRNA) as a model molecule, this study was to define the in vitro and in vivo knockdown efficiency of BERAs delivered by liposome-polyethylenimine nanocomplex (lipopolyplex or LPP...
Source: International Journal of Pharmaceutics - June 18, 2018 Category: Drugs & Pharmacology Source Type: research

lncRNA ZEB1-AS1 Mediates Oxidative Low-Density Lipoprotein-Mediated Endothelial Cells Injury by Post-transcriptional Stabilization of NOD2
Conclusion We report the discovery that ZEB1-AS1 functionally participates in ox-LDL-induced ECs injury via LRPPRC-mediated stabilization of NOD2. Uncovering the precise role of ZEB1-AS1/LRPPRC/NOD2 pathway in the progression of ox-LDL-induced ECs death and AS will not only increase our knowledge of ox-LDL-induced AS, but also enable the development of novel therapeutic strategies to overcome oxidation product-induced diseases. Author Contributions XX and CL designed and mainly did the study. CM, ZD, and YD helped and did the study. Conflict of Interest Statement The authors declare that the research was conducted in ...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research